JBCHEPHARM JB Chemicals & Pharmaceuticals Q3 FY26 results (Oct–Dec 2025) and concall
JB Chemicals & Pharmaceuticals Limited delivered a strong Q3 FY26, with revenues growing 11% to INR1,065 crore and net profit increasing 22% to INR198 crore. The company saw significant margin expansion, with gross margins up 200 bps to 69.1% and operating EBITDA margin at 28.7%. Domestic business outpaced the IPM with 10% growth, and international formulations grew 20%, though the CDMO segment remained flat. The company reiterated its FY26 operating margin guidance of 27-29% and expects continued outperformance in India and high single-digit growth internationally.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 8.4%, net profit up 14.7% against the same quarter last year.
| Line item | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 952 | 956 | 914 | 901 | 1,040 +9% | 1,023 +7% | 991 +8% |
| EBITDA | 273 | 268 | 245 | 231 | 293 +7% | 298 +11% | 270 +10% |
| Net profit | 173 | 173 | 156 | 150 | 198 +14% | 200 +16% | 179 +15% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
